Defence Therapeutics

Defence Therapeutics is a scientific pioneer on a journey to uncover enhanced treatment solutions for future generations through biopharmaceutical innovations.

<div>Defence Therapeutics is a Canadian biopharmaceutical company focused on developing innovative immune-oncology vaccines and drug delivery technologies. The company's core technology, the Accum platform, enables precise delivery of vaccine antigens and antibody-drug conjugates (ADCs) to target cells, potentially improving efficacy against cancer and infectious diseases. Defence's lead product, AccuTOX, is a cancer-killing technology that has shown promise in preclinical studies for treating various types of tumors, including lung, breast, colon, melanoma, and lymphoma. In March 2024, Defence was awarded a US patent for AccuTOX, providing market exclusivity until late 2042. The company is also developing AccuTRIC, a novel Radio-Immuno-Conjugate (RIC) that combines AccuTOX with Auger electron emitter elements to treat hard-to-treat cancers. In July 2024, Defence received approval from Health Canada to commence a Phase I clinical trial evaluating AccuTOX as a monotherapy and in combination with Opdualag for patients with unresectable stage IIIB to IV melanoma.</div>

Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology

Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024

Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology

Perspectives on Cancer Treatment: Defence Therapeutics in Focus with Ellis Martin | Eulerpool News

Bringing Life-Saving Biologics to More Patients

Biosimilars

Defence Therapeutics’ ARM-X cancer vaccine effective in ovarian cancer models

<div>
 
 Defence Therapeutics is a Canadian biopharmaceutical company focused on developing innovative immune-oncology vaccines and drug delivery technologies. The company's core technology, the Accum platform, enables precise delivery of vaccine antigens and antibody-drug conjugates (ADCs) to target cells, potentially improving efficacy against cancer and infectious diseases. Defence's lead product, AccuTOX, is a cancer-killing technology that has shown promise in preclinical studies for treating various types of tumors, including lung, breast, colon, melanoma, and lymphoma. In March 2024, Defence was awarded a US patent for AccuTOX, providing market exclusivity until late 2042. The company is also developing AccuTRIC, a novel Radio-Immuno-Conjugate (RIC) that combines AccuTOX with Auger electron emitter elements to treat hard-to-treat cancers. In July 2024, Defence received approval from Health Canada to commence a Phase I clinical trial evaluating AccuTOX as a monotherapy and in combination with Opdualag for patients with unresectable stage IIIB to IV melanoma.
 
</div>

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer treatment. The company's strategy revolves around building a leading immuno-oncology franchise funded by cash generated from its portfolio of FDA-approved therapeutics. Coherus markets several biosimilar products in the US, including UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
In July 2023, Coherus launched YUSIMRY at a list price of USD 995 per carton for two 40 mg/0.8 mL autoinjectors, representing a discount of more than 85% compared to Humira. This pricing strategy aims to improve patient access to adalimumab treatment by offering significant cost savings. YUSIMRY is indicated for various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Coherus is also developing toripalimab, an anti-PD-1 antibody, for the US and Canadian markets through a licensing agreement with Shanghai Junshi Biosciences Ltd. A Biologics License Application (BLA) for toripalimab in combination with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma was under FDA review.
In March 2024, Coherus reported net revenue of USD 91.5 million for Q4 2023 and USD 257.2 million for the full year 2023, driven by sales of UDENYCA and CIMERLI. However, the company faced challenges, including a net loss of USD 79.7 million in Q4 and USD 237.9 million for the full year 2023. To address these challenges, Coherus initiated a workforce reduction of 30% to streamline operations and focus on oncology.

Coherus Biosciences

Custom Biologics is a Canadian contract research organization (CRO) specializing in bioanalytical services for biopharmaceuticals, vaccines, and cell and gene therapy products. With over 20 years of experience, the company focuses on designing and validating regulatory compliant assays for functional characterization, potency/bioactivity assessments, clinical pharmacokinetics, and immunogenicity of biotherapeutic drugs. Custom Biologics' genomics group develops molecular genetic assays for gene and genome analysis, measuring genetic inserts and transgenes in gene therapy vectors, oncolytic viruses, and nucleic acid-based vaccines. The company has also developed a proprietary isothermal nucleic acid amplification technology called DASL-RAPID for rapid identification of human and food-borne pathogens. Custom Biologics maintains a Health Canada cGMP Drug Establishment License and operates under a quality system based on FDA and EMEA GLP guidelines. The company's services are utilized in preclinical research and development programs, as well as for validated GMP-compliant assays suitable for stability analysis, clinical analysis, and clinical/market lot release testing. Custom Biologics employs state-of-the-art bioanalytical laboratory equipment and sophisticated statistical software to generate data for submissions to regulatory agencies worldwide.

Custom Biologics

CuriRx, Inc., founded in 2012, is a contract development and manufacturing organization (CDMO) based in Wilmington, Massachusetts. The company specializes in providing end-to-end support for biotherapeutic drug developers, focusing on complex molecules such as recombinant proteins, monoclonal antibodies, bispecific antibodies, vaccines, antibody drug conjugates, oligonucleotides, and gene therapy products. CuriRx's services encompass upstream and downstream process development, optimization, characterization, scale-up and scale-down, analytical development, formulation development, and lyophilization.
In January 2022, CuriRx launched its Advanced Bioprocessing and Analytical Center, which combines state-of-the-art bioprocessing laboratories with the CuriLytics Platform's high-resolution analytical instrumentation. This center aims to accelerate biotherapeutic drug development by leveraging the team's extensive bioprocessing experience and employing the latest methods in upstream and downstream process development. The CuriLytics Platform utilizes high-resolution mass spectrometry and various orthogonal characterization methods to further de-risk drug development.
CuriRx has the capacity to produce non-GMP vials for animal studies and non-GMP stability support studies. The company's key personnel have been involved in successful development projects for notable drugs such as HUMIRA, SYNAGIS, BLINCYTO, and GATTEX. In September 2013, CuriRx was awarded a five-year contract by the National Cancer Institute for the development and production of oncology products, demonstrating its expertise in the field.

CuriRx

Paras Biopharmaceuticals Finland Oy is a biopharmaceutical technology development company based in Oulu, Finland. Founded in 2012, the company specializes in the development and manufacturing of complex biologics and biosimilars using microbial expression systems. Paras Biopharmaceuticals operates a state-of-the-art 25,000 square foot biologics production facility in Finland, which includes 4,300 square feet of classified cleanroom space. The facility is equipped for media and buffer preparation, fermentation, harvest and extraction, purification, final filtration, and freeze-drying.
The company's core activities are divided into two main divisions: Paras Biopharma, which focuses on biologics Contract Development and Manufacturing Organization (CDMO) services, and Paras Biologics, which handles biosimilar development and licensing. Paras Biopharmaceuticals has developed proprietary technology platforms including Biomultifold, Noblecleav, and Cytofold StructQuant to achieve high productivity and quality in biologics manufacturing. These technologies enable the company to produce complex proteins and biosimilars cost-effectively at scale.
As of December 2022, Paras Biopharmaceuticals reported achieving success with "Continuous Biomanufacturing" for high-value onco-immunology and urology biosimilars. The company has also made advancements in maximizing recombinant protein expression in microbial systems, reporting expression levels of up to 12g/L or more of fully folded, biologically active protein in fermentation broth as of July 2023.

Paras Biopharmaceuticals

Kashiv Biosciences, LLC is a fully integrated biopharmaceutical company focused on developing biosimilars and specialty biopharmaceutical products. The company has global research and development, clinical, regulatory, and manufacturing capabilities. Kashiv utilizes its MayaBio reactor technology to develop biosimilars. The company's product portfolio includes biosimilars targeting conditions such as asthma, chronic idiopathic urticaria, and neutropenia. Kashiv's lead biosimilar candidate, ADL018, is a proposed biosimilar to Xolair (omalizumab) currently in Phase III clinical trials for chronic spontaneous urticaria. In March 2022, Kashiv received FDA approval for its first biosimilar RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen. The company has a robust pipeline of seven biosimilars and multiple 505(b)(2) and complex peptide generic products in development. Kashiv operates FDA-approved GMP manufacturing facilities in Chicago, Illinois and has state-of-the-art R&D infrastructure in Ahmedabad, India. The company is headquartered in Piscataway, New Jersey.
Key customers and partnerships
Kashiv has established strategic partnerships to commercialize its products globally. In October 2023, Kashiv entered into an exclusive licensing agreement with Alvotech for the development and commercialization of ADL018 in Europe, the UK, Australia, Canada, and New Zealand. In July 2024, Kashiv signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018 in the US. Kashiv has also collaborated with Amneal on the development and commercialization of other biosimilars, including RELEUKO and FYLNETRA. These partnerships allow Kashiv to leverage its partners' commercial expertise and global reach to bring its biosimilar products to market.

Kashiv Biosciences

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

AI/ML-driven technology platforms support drug design and development process and integration of drug substance development

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

PROMINENT_CATEGORY

<div>

 Defence Therapeutics is set to license its Accum technology to the biotech and pharmaceutical sectors. This innovative tech aims to enhance the efficacy of antibody-drug conjugates (ADCs).
 Accum is engineered to optimize the delivery and potency of various biotherapeutics such as ADCs, vaccines, protein therapeutics, and radiopharmaceuticals, by evading endosomal entrapment which is a significant roadblock in drug delivery systems. This advancement could potentially amplify the power of treatments, particularly in immunotherapy and oncology.
 Defence Therapeutics, headquartered in Canada, is centred around the progress of ADCs, radiopharmaceuticals, and immune-oncology vaccines. The heart of the company's technology lies in the ACCUM platform that increases the delivery of drugs, antigens, or proteins into targeted cells. By making use of this platform, the precise delivery of ADCs or radio-immuno-conjugates in their complete form to target cells is made possible, thereby enhancing the efficiency of treatments against cancer and infections. A notable development from the company is AccuTOX - a cancer treatment currently in Phase I clinical trials, aiming to treat unresectable stage IIIB to IV melanoma.
 
</div>

Defence Therapeutics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless